Beate Sander, Sharmistha Mishra, Sarah Swayze, Yeva Sahakyan, Raquel Duchen, Kieran Quinn, Naveed Janjua, Hind Sbihi, Jeffrey Kwong
{"title":"Population-Based Matched Cohort Study of COVID-19 Healthcare Costs, Ontario, Canada.","authors":"Beate Sander, Sharmistha Mishra, Sarah Swayze, Yeva Sahakyan, Raquel Duchen, Kieran Quinn, Naveed Janjua, Hind Sbihi, Jeffrey Kwong","doi":"10.3201/eid3104.241463","DOIUrl":null,"url":null,"abstract":"<p><p>Estimates of COVID-19-related healthcare costs are key to health system planning, but attributable cost data remain limited. We characterized healthcare costs attributable to COVID-19 through a population-based matched cohort study in Ontario, Canada, by using health administrative data. We matched SARS-CoV-2-positive persons from 2020 to unexposed historical control persons from 2016-2018. We estimated phase-based and survival-adjusted COVID-19-attributable healthcare costs from the health system perspective. We matched 159,817 persons. Mean (95% CI) attributable 10-day costs per person were $1 ($-4 to $6) preindex, $240 ($231-$249) during acute care, $18 ($14-$21) in postacute phases, $3,928 ($3,471-$4,384) in the terminal phase for early deaths, and $1,781 ($1,182-$2,380) for late deaths. Mean cumulative survival-adjusted cost at 360 days was $2,553 ($2,348-$2,756) per person. SARS-CoV-2 infection is associated with substantial long-term healthcare costs, consistent with understanding of post-COVID condition. Determining phase-specific costs can inform budget and pandemic planning.</p>","PeriodicalId":11595,"journal":{"name":"Emerging Infectious Diseases","volume":"31 4","pages":"710-719"},"PeriodicalIF":7.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3201/eid3104.241463","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Estimates of COVID-19-related healthcare costs are key to health system planning, but attributable cost data remain limited. We characterized healthcare costs attributable to COVID-19 through a population-based matched cohort study in Ontario, Canada, by using health administrative data. We matched SARS-CoV-2-positive persons from 2020 to unexposed historical control persons from 2016-2018. We estimated phase-based and survival-adjusted COVID-19-attributable healthcare costs from the health system perspective. We matched 159,817 persons. Mean (95% CI) attributable 10-day costs per person were $1 ($-4 to $6) preindex, $240 ($231-$249) during acute care, $18 ($14-$21) in postacute phases, $3,928 ($3,471-$4,384) in the terminal phase for early deaths, and $1,781 ($1,182-$2,380) for late deaths. Mean cumulative survival-adjusted cost at 360 days was $2,553 ($2,348-$2,756) per person. SARS-CoV-2 infection is associated with substantial long-term healthcare costs, consistent with understanding of post-COVID condition. Determining phase-specific costs can inform budget and pandemic planning.
期刊介绍:
Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination.
Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.